Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Odyssey Health, Inc. (ODYY)
USD0.01
+0.00 (+16.67%)
US OTC Healthcare Medical - Devices
Address
2300 West Sahara Avenue 89102
Las Vegas, NV, US
Las Vegas, NV, US
CEO
Joseph Michael Redmond
Website
odysseyhealthinc.com
IPO
2021-01-08
CIK 1626644 ISIN US67612C1027
Description
Odyssey Health, Inc. operates as a medical enterprise, primarily focused on the innovation and development of diverse healthcare products. Its current portfolio encompasses CardioMap, an advanced device for cardiac monitoring and screening, alongside the "Save A Life" line of devices engineered for choking emergencies. Additionally, the company is advancing neurosteroid drug compounds, PRV-001 and PRV-002, intended for the treatment of concussive injuries and various rare brain disorders. The organization, established in 2014 and headquartered in Las Vegas, Nevada, was previously known as Odyssey Group International, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+16.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
203.4K
Beta
-1.46
Float Shares
84.01M
Free Float %
84.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.11% | -48.15% | -72.71% | -87.27% | -77.94% | -78.72% | -36.07% | -90.80% | -98.91% | -97.45% | -97.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.01
Quality scores
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%-78.5% Q2'26: +395.8% (vs Q2'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q2'26: +0.0% (vs Q2'25)
-
Share dilution Medical - Devices: 0.0%+7.9% Q2'26: +3.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.33× Q2'26: -2.22× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-620.5K
OE per share TTM
-0.01
Owner's Yield
-82.19%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jonathan D. Lutz | 4.70M | 5.90% | 4.70M | — | 4.70M | — | IN | United States | 2023-07-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Ratio by volume
1.05
Neutral
Buys
3
Sells
1
Shares acquired
1.58M
Shares disposed
1.50M
Cash buys
—
Cash sales
—
Net activity
+75,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-28 | RICHARDSON RICKY | Director | A-Award | A | Stock Option (Right to Buy | 300,000 | 0.10 | 30.0K | 300,000 | — | ↗ |
| 2024-06-28 | REDMOND J MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.10 | 50.0K | 500,000 | — | ↗ |
| 2024-06-28 | Gironda Gregory W | Officer | A-Award | A | Stock Option (Right to Buy | 250,000 | 0.10 | 25.0K | 250,000 | — | ↗ |
| 2024-06-28 | FARRELL CHRISTINE | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.10 | 50.0K | 500,000 | — | ↗ |
| 2024-06-28 | Casey Jerome H | Director | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.10 | 30.0K | 300,000 | — | ↗ |
| 2024-01-16 | Gironda Gregory W | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 0.09 | 3.2K | 37,500 | — | ↗ |
| 2024-01-16 | Emerson Erik C. | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 0.09 | 3.2K | 37,500 | — | ↗ |
| 2024-01-10 | GANDOLFO JOHN P | Director | A-Award | A | ODYY - Common Stock | 1,500,000 | 0.09 | 135.0K | 1,738,792 | — | ↗ |
| 2023-12-29 | RICHARDSON RICKY | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.10 | 25.0K | 250,000 | — | ↗ |
| 2023-12-29 | REDMOND J MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.10 | 50.0K | 500,000 | — | ↗ |
| 2023-12-29 | Gironda Gregory W | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.10 | 20.0K | 200,000 | — | ↗ |
| 2023-12-29 | FARRELL CHRISTINE | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.10 | 50.0K | 500,000 | — | ↗ |
| 2023-12-29 | Emerson Erik C. | — | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.10 | 20.0K | 200,000 | — | ↗ |
| 2023-12-29 | Casey Jerome H | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.10 | 25.0K | 250,000 | — | ↗ |
| 2023-01-12 | RICHARDSON RICKY | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.30 | 150.0K | 1,000,000 | — | ↗ |
| 2023-01-12 | REDMOND J MICHAEL | Officer | A-Award | A | Restricted Stock Unit (Right to Buy) | 400,000 | 0.30 | 120.0K | 3,500,000 | — | ↗ |
| 2023-01-12 | GANDOLFO JOHN P | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.30 | 150.0K | 1,500,000 | — | ↗ |
| 2023-01-12 | FARRELL CHRISTINE | Officer | A-Award | A | Restricted Stock Unit (Right to Buy) | 400,000 | 0.30 | 120.0K | 1,700,000 | — | ↗ |
| 2023-01-12 | Casey Jerome H | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.30 | 150.0K | 1,500,000 | — | ↗ |
| 2022-11-01 | Gironda Gregory W | Director | A-Award | A | Stock Option - Right to buy | 125,000 | 0.25 | 31.3K | 125,000 | — | ↗ |
| 2022-11-01 | Emerson Erik C. | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-10-14 | VANLANDINGHAM JACOB PH.D | Director | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 0.32 | 318.0K | 2,100,000 | — | ↗ |
| 2022-10-14 | FARRELL CHRISTINE | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.32 | 159.0K | 1,100,000 | — | ↗ |
| 2022-06-10 | VANLANDINGHAM JACOB PH.D | Director | A-Award | A | ODYY common stock $0.001 par value | 1,000,000 | 0.23 | 230.0K | 9,660,000 | — | ↗ |
| 2022-05-19 | VANLANDINGHAM JACOB PH.D | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.30 | 30.0K | 1,100,000 | — | ↗ |
| 2022-05-19 | RICHARDSON RICKY | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.30 | 75.0K | 1,000,000 | — | ↗ |
| 2022-05-19 | REDMOND J MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.30 | 112.5K | 3,750,000 | — | ↗ |
| 2022-05-19 | GANDOLFO JOHN P | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.30 | 75.0K | 1,500,000 | — | ↗ |
| 2022-05-19 | FARRELL CHRISTINE | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.30 | 90.0K | 1,600,000 | — | ↗ |
| 2022-05-19 | Conroy Jeffrey X | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.30 | 75.0K | 1,500,000 | — | ↗ |
| 2022-05-19 | Casey Jerome H | Director | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.30 | 75.0K | 1,250,000 | — | ↗ |
| 2021-09-14 | GANDOLFO JOHN P | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.45 | 225.0K | 1,000,000 | — | ↗ |
| 2021-09-14 | Conroy Jeffrey X | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.45 | 225.0K | 1,000,000 | — | ↗ |
| 2021-09-14 | Casey Jerome H | Director | A-Award | A | Restricted Stock Unit (Right to Buy) | 500,000 | 0.45 | 225.0K | 1,000,000 | — | ↗ |
| 2021-05-06 | RICHARDSON RICKY | Director | — | D | Restricted Stock Unit (Right to Buy) | 500,000 | 0.00 | — | 0 | — | ↗ |
| 2021-03-01 | VANLANDINGHAM JACOB PH.D | Director | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 1.18 | 1.18M | 1,000,000 | — | ↗ |
| 2021-01-01 | REDMOND J MICHAEL | Director / Officer | A-Award | A | Restricted Stock Unit (Right to Buy | 3,000,000 | 0.18 | 540.0K | 3,000,000 | — | ↗ |
| 2021-01-01 | FARRELL CHRISTINE | Officer | A-Award | A | Restricted Stock Unit (Right to Buy) | 1,000,000 | 0.18 | 180.0K | 1,000,000 | — | ↗ |
| 2020-09-16 | REDMOND J MICHAEL | Director / Officer | J-Other | D | ODYY - Common Stock Option | 15,000,000 | 0.25 | 3.75M | 3,000,000 | — | ↗ |
| 2020-03-09 | FARRELL CHRISTINE | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2019-10-23 | GANDOLFO JOHN P | Director | — | D | Restricted Stock Unit (Right to Buy) | 500,000 | 0.00 | — | 0 | — | ↗ |
| 2019-09-20 | Casey Jerome H | Director | — | D | Restricted Stock Unit (Right to Buy) | 500,000 | 0.00 | — | 0 | — | ↗ |
| 2019-08-28 | Conroy Jeffrey X | Director | — | D | Restricted Stock Unit (Right to Buy) | 500,000 | 0.00 | — | 0 | — | ↗ |
| 2019-06-25 | VANLANDINGHAM JACOB PH.D | Director | — | D | ODYY - Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2018-11-28 | REDMOND J MICHAEL | Director / Officer | — | D | ODYY - Common Stock | 0 | 0.00 | — | 4,700,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
99.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2020 | Christine M. Farrell Chief Financial Officer and Secretary | 15.0K | — | 448.0K | — | — | — | 463.0K | 96.76% | ↗ |
| 2 | 2020 | Joseph Michael Redmond President, Chief Executive Officer and Chairman | 161.5K | — | — | — | — | — | 161.5K | 0.00% | ↗ |
| 3 | 2019 | Joseph Michael Redmond President, Chief Executive Officer and Chairman | 18.5K | — | 47.0K | — | — | — | 65.5K | 71.80% | ↗ |
| 4 | 2019 | Christine M. Farrell Chief Financial Officer and Secretary | 15.0K | — | 6.0K | — | — | — | 21.0K | 28.57% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph Michael Redmond | Chairman, President & Chief Executive Officer | 191.9K | male |
| Christine Farrell | Chief Financial Officer & Secretary | 106.6K | female |
| Greg Gironda | Chief Operating Officer | — | male |
| Michael Contarino | Head of Product Development | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ODYY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
